Amyloidosis is the basis of several serious diseases, such as Alzheimer disease and Parkinson disease. This process involves the formation of amyloid fibrils, crystal-like collections of misfolded ...

Healio spoke with Joban Vaishnav, MD, director of the Johns Hopkins Comprehensive Amyloidosis Center, about the process of diagnosing amyloidosis, the importance of multidisciplinary care in ...

Seeing a mental health professional or therapist—especially one who is experienced treating people with serious diseases—can ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Lower skeletal muscle mass was associated with an increased risk for short- and long-term mortality in patients with cardiac amyloidosis (CA). This association was particularly strong with ...

which argued that NICE had acted unfairly by failing to invite an AL amyloidosis expert or a haematologist to participate in the review process. The guidance also ends a disparity in access within ...

The RMAT designation could expedite the development and approval process, offering Immix Biopharma ... the safety and efficacy of NXC-201 in AL amyloidosis patients. NXC-201 is the only CAR ...

Alnylam's gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available on the ...